Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Exposure-response analyses of tigecycline tolerability in healthy subjects.

Passarell J, Ludwig E, Liolios K, Meagher AK, Grasela TH, Babinchak T, Ellis-Grosse EJ.

Diagn Microbiol Infect Dis. 2009 Oct;65(2):123-9. doi: 10.1016/j.diagmicrobio.2009.06.019.

PMID:
19748422
2.

Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci.

Ambrose PG, Meagher AK, Passarell JA, Van Wart SA, Cirincione BB, Bhavnani SM, Ellis-Grosse E.

Diagn Microbiol Infect Dis. 2009 Feb;63(2):155-9. doi: 10.1016/j.diagmicrobio.2008.10.011.

PMID:
19150707
3.

Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.

Ambrose PG, Meagher AK, Passarell JA, Van Wart SA, Cirincione BB, Rubino CM, Korth-Bradley JM, Babinchak T, Ellis-Grosse E.

Diagn Microbiol Infect Dis. 2009 Jan;63(1):38-42. doi: 10.1016/j.diagmicrobio.2008.09.014.

PMID:
19073300
4.

Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections.

Passarell JA, Meagher AK, Liolios K, Cirincione BB, Van Wart SA, Babinchak T, Ellis-Grosse EJ, Ambrose PG.

Antimicrob Agents Chemother. 2008 Jan;52(1):204-10. Epub 2007 Oct 22.

5.

Population pharmacokinetics of tigecycline in healthy volunteers.

Van Wart SA, Cirincione BB, Ludwig EA, Meagher AK, Korth-Bradley JM, Owen JS.

J Clin Pharmacol. 2007 Jun;47(6):727-37.

PMID:
17519399
6.

Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.

Meagher AK, Passarell JA, Cirincione BB, Van Wart SA, Liolios K, Babinchak T, Ellis-Grosse EJ, Ambrose PG.

Antimicrob Agents Chemother. 2007 Jun;51(6):1939-45. Epub 2007 Mar 12.

7.

Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections.

Van Wart SA, Owen JS, Ludwig EA, Meagher AK, Korth-Bradley JM, Cirincione BB.

Antimicrob Agents Chemother. 2006 Nov;50(11):3701-7. Epub 2006 Aug 28.

8.

Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent.

Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ.

Diagn Microbiol Infect Dis. 2005 Jul;52(3):165-71. Review.

PMID:
16105560
9.

The pharmacokinetic and pharmacodynamic profile of tigecycline.

Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ.

Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S333-40. Review.

PMID:
16080071
10.

Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin.

Meagher AK, Forrest A, Dalhoff A, Stass H, Schentag JJ.

Antimicrob Agents Chemother. 2004 Jun;48(6):2061-8.

11.

Linezolid in the treatment of osteomyelitis: results of compassionate use experience.

Rayner CR, Baddour LM, Birmingham MC, Norden C, Meagher AK, Schentag JJ.

Infection. 2004 Feb;32(1):8-14.

PMID:
15007736
12.

Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme.

Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ.

Clin Pharmacokinet. 2003;42(15):1411-23.

PMID:
14674791
13.

Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials.

Schentag JJ, Meagher AK, Forrest A.

Ann Pharmacother. 2003 Oct;37(10):1478-88. Review.

PMID:
14519053
14.

Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models.

Schentag JJ, Meagher AK, Forrest A.

Ann Pharmacother. 2003 Sep;37(9):1287-98. Review.

PMID:
12921513
15.

Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia.

Smith PF, Birmingham MC, Noskin GA, Meagher AK, Forrest A, Rayner CR, Schentag JJ.

Ann Oncol. 2003 May;14(5):795-801.

PMID:
12702536
16.

Population pharmacokinetics of linezolid in patients treated in a compassionate-use program.

Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ.

Antimicrob Agents Chemother. 2003 Feb;47(2):548-53.

17.

Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program.

Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ.

Clin Infect Dis. 2003 Jan 15;36(2):159-68. Epub 2003 Jan 3.

PMID:
12522747

Supplemental Content

Loading ...
Support Center